REFERENCES

1. Behranvand N, Nasri F, Zolfaghari Emameh R, et al. Chemotherapy: a double-edged sword in cancer treatment. Cancer Immunol Immunother. 2022;71:507-26.

2. Gridelli C, Peters S, Mok T, et al. Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: results of an international expert panel meeting by the italian association of thoracic oncology (AIOT). Lung Cancer. 2024;187:107441.

3. Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, et al. Chemo-immunotherapy: a new trend in cancer treatment. Cancers. 2023;15:2912.

4. Hendriks LEL, Remon J, Faivre-Finn C, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024;10:71.

5. Kuderer NM, Desai A, Lustberg MB, Lyman GH. Mitigating acute chemotherapy-associated adverse events in patients with cancer. Nat Rev Clin Oncol. 2022;19:681-97.

6. Yazbeck V, Alesi E, Myers J, Hackney MH, Cuttino L, Gewirtz DA. An overview of chemotoxicity and radiation toxicity in cancer therapy. Adv Cancer Res. 2022;155:1-27.

7. Ioele G, Chieffallo M, Occhiuzzi MA, et al. Anticancer drugs: recent strategies to improve stability profile, pharmacokinetic and pharmacodynamic properties. Molecules. 2022;27:5436.

8. Rezakhani L, Fekri K, Rostaminasab G, Rahmati S. Exosomes: special nano-therapeutic carrier for cancers, overview on anticancer drugs. Med Oncol. 2022;40:31.

9. Ulldemolins A, Seras-Franzoso J, Andrade F, et al. Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics. Cancer Drug Resist. 2021;4:44-68.

10. Wang B, Hu S, Teng Y, et al. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther. 2024;9:200.

11. Sen S, Xavier J, Kumar N, Ahmad MZ, Ranjan OP. Exosomes as natural nanocarrier-based drug delivery system: recent insights and future perspectives. 3 Biotech. 2023;13:101.

12. Brezgin S, Danilik O, Yudaeva A, et al. Basic guide for approaching drug delivery with extracellular vesicles. Int J Mol Sci. 2024;25:10401.

13. Liu X, Cao Y, Wang S, Liu J, Hao H. Extracellular vesicles: powerful candidates in nano-drug delivery systems. Drug Deliv Transl Res. 2024;14:295-311.

14. Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for drug delivery. Adv Drug Deliv Rev. 2016;106:148-56.

15. Samanta S, Rajasingh S, Drosos N, Zhou Z, Dawn B, Rajasingh J. Exosomes: new molecular targets of diseases. Acta Pharmacol Sin. 2018;39:501-13.

16. Sutaria DS, Badawi M, Phelps MA, Schmittgen TD. Achieving the promise of therapeutic extracellular vesicles: the devil is in details of therapeutic loading. Pharm Res. 2017;34:1053-66.

17. Batrakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release. 2015;219:396-405.

18. Chen C, Pan X, Sun M, et al. Phospholipid-anchored ligand conjugation on extracellular vesicles for enhanced cancer targeting. Small. 2024;20:e2310712.

19. Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021;16:748-59.

20. Zhang M, Hu S, Liu L, et al. Engineered exosomes from different sources for cancer-targeted therapy. Signal Transduct Target Ther. 2023;8:124.

21. Antimisiaris SG, Mourtas S, Marazioti A. Exosomes and exosome-inspired vesicles for targeted drug delivery. Pharmaceutics. 2018;10:218.

22. Familtseva A, Jeremic N, Tyagi SC. Exosomes: cell-created drug delivery systems. Mol Cell Biochem. 2019;459:1-6.

23. Jaiswal N, Mahata N, Chanda N. Nanogold-albumin conjugates: transformative approaches for next-generation cancer therapy and diagnostics. Nanoscale. 2025;17:11191-220.

24. Lee JW, Choi SR, Heo JH. Simultaneous stabilization and functionalization of gold nanoparticles via biomolecule conjugation: progress and perspectives. ACS Appl Mater Interfaces. 2021;13:42311-28.

25. Kesharwani P, Ma R, Sang L, et al. Gold nanoparticles and gold nanorods in the landscape of cancer therapy. Mol Cancer. 2023;22:98.

26. Kim Y, Mondal S, Shin H, et al. Advanced precision dual photothermal and photodynamic therapy for prostate cancer using PSMA-ICG-conjugated gold nanorods. ACS Biomater Sci Eng. 2025;11:3376-88.

27. Zhao T, Ren M, Shi J, et al. Engineering the protein corona: strategies, effects, and future directions in nanoparticle therapeutics. Biomed Pharmacother. 2024;175:116627.

28. Bolaños K, León D, Jara-Guajardo P, et al. In vivo targeted delivery of extracellular vesicle‒gold nanorod hybrids to metastatic melanoma lung tumors. Int J Nanomedicine. 2025;20:6983-98.

29. Srinivasarao M, Low PS. Ligand-targeted drug delivery. Chem Rev. 2017;117:12133-64.

30. Sundaram V, Aryal S. Emerging biomimetic drug delivery nanoparticles inspired by extracellular vesicles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025;17:e70025.

31. Johnson V, Vasu S, Kumar US, Kumar M. Surface-engineered extracellular vesicles in cancer immunotherapy. Cancers. 2023;15:2838.

32. Amreddy N, Muralidharan R, Babu A, et al. Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy. Int J Nanomedicine. 2015;10:6773-88.

33. Lan X, Wang X, Shao L, et al. Effect of transferrin-modified Fe₃O₄ nanoparticle targeted delivery miR-15a-5p combined with photothermal therapy on lung cancer. Thorac Cancer. 2025;16:e15497.

34. Nguyen NT, Nguyen NNT, Tran NTN, et al. Synergic activity against MCF-7 breast cancer cell growth of nanocurcumin-encapsulated and cisplatin-complexed nanogels. Molecules. 2018;23:3347.

35. Zhang Z, Chen J, Wen T, et al. Quantification of cisplatin encapsulated in nanomedicine: an overview. Biosensors. 2025;15:293.

36. Inoue S, Hartman A, Branch CD, et al. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther. 2007;15:287-94.

37. Muralidharan R, Babu A, Amreddy N, et al. Tumor-targeted nanoparticle delivery of HuR siRNA inhibits lung tumor growth in vitro and in vivo by disrupting the oncogenic activity of the RNA-binding protein HuR. Mol Cancer Ther. 2017;16:1470-86.

38. Welsh JA, Goberdhan DCI, O’Driscoll L, et al.; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404.

39. Jeppesen DK, Fenix AM, Franklin JL, et al. Reassessment of exosome composition. Cell. 2019;177:428-45.e18.

40. Fathy MM, Elfiky AA, Bashandy YS, et al. An insight into synthesis and antitumor activity of citrate and gallate stabilizing gold nanospheres. Sci Rep. 2023;13:2749.

41. Zhou W, Gao X, Liu D, Chen X. Gold nanoparticles for in vitro diagnostics. Chem Rev. 2015;115:10575-636.

42. Beit-Yannai E, Tabak S, Stamer WD. Physical exosome:exosome interactions. J Cell Mol Med. 2018;22:2001-6.

43. Dreyer F, Baur A. Biogenesis and functions of exosomes and extracellular vesicles. Methods Mol Biol. 2016;1448:201-16.

44. Persi E, Duran-Frigola M, Damaghi M, et al. Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun. 2018;9:2997.

45. Sergeeva TF, Shirmanova MV, Zlobovskaya OA, et al. Relationship between intracellular pH, metabolic co-factors and caspase-3 activation in cancer cells during apoptosis. Biochim Biophys Acta Mol Cell Res. 2017;1864:604-11.

46. Kennedy L, Sandhu JK, Harper ME, Cuperlovic-Culf M. Role of glutathione in cancer: from mechanisms to therapies. Biomolecules. 2020;10:1429.

47. Li Y, An L, Lin J, Tian Q, Yang S. Smart nanomedicine agents for cancer, triggered by pH, glutathione, H₂O₂, or H₂S. Int J Nanomedicine. 2019;14:5729-49.

48. Liu G, Zhao X, Zhang Y, et al. Engineering biomimetic platesomes for pH-responsive drug delivery and enhanced antitumor activity. Adv Mater. 2019;31:e1900795.

49. Ciccotosto G, Jana M, Galluzzi L, et al. A novel pH-sensitive probe to quantify autophagy on high throughput/content imaging platforms. BioRxiv. 2025.

50. Koltai T, Reshkin SJ, Harguindey S. Chapter 3 - The pH-centered paradigm in cancer. In An innovative approach to understanding and treating cancer: targeting pH. Elsevier; 2020. pp. 53-97.

51. Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol. 2018;31:15-25.

52. Calzolari A, Oliviero I, Deaglio S, et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis. 2007;39:82-91.

53. Liu Y, Crawford BM, Vo-Dinh T. Gold nanoparticles-mediated photothermal therapy and immunotherapy. Immunotherapy. 2018;10:1175-88.

54. Zhou M, Zhou Y, Cheng Y, Wu Y, Yang J, Lv Z. Application of gold-based nanomaterials in tumor photothermal therapy and chemotherapy. J Biomed Nanotechnol. 2020;16:739-62.